JP2013536408A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536408A5
JP2013536408A5 JP2013518767A JP2013518767A JP2013536408A5 JP 2013536408 A5 JP2013536408 A5 JP 2013536408A5 JP 2013518767 A JP2013518767 A JP 2013518767A JP 2013518767 A JP2013518767 A JP 2013518767A JP 2013536408 A5 JP2013536408 A5 JP 2013536408A5
Authority
JP
Japan
Prior art keywords
composition
maximum threshold
less
item
statin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536408A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042846 external-priority patent/WO2012003475A1/en
Publication of JP2013536408A publication Critical patent/JP2013536408A/ja
Publication of JP2013536408A5 publication Critical patent/JP2013536408A5/ja
Pending legal-status Critical Current

Links

JP2013518767A 2010-07-02 2011-07-01 ガレクチン−３測定によりモニタリングされるスタチン療法 Pending JP2013536408A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36121610P 2010-07-02 2010-07-02
US61/361,216 2010-07-02
PCT/US2011/042846 WO2012003475A1 (en) 2010-07-02 2011-07-01 Statin therapy monitored by galectin- 3 measurement

Publications (2)

Publication Number Publication Date
JP2013536408A JP2013536408A (ja) 2013-09-19
JP2013536408A5 true JP2013536408A5 (https=) 2014-08-07

Family

ID=44628757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518767A Pending JP2013536408A (ja) 2010-07-02 2011-07-01 ガレクチン−３測定によりモニタリングされるスタチン療法

Country Status (4)

Country Link
US (1) US20120029003A1 (https=)
EP (1) EP2588111A1 (https=)
JP (1) JP2013536408A (https=)
WO (1) WO2012003475A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
BR112012008063A2 (pt) 2009-08-25 2016-11-22 Bg Medicine Inc galectina-3 e terapia de ressincronização cardíaca.
WO2013169890A1 (en) * 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
EP3441768A3 (en) 2013-08-26 2019-03-20 Roche Diagnostics GmbH Marker for statin treatment stratification in heart failure
EP3470848A3 (en) 2014-01-28 2019-05-22 Roche Diagnostics GmbH Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
CA3238590A1 (en) * 2021-11-09 2023-05-19 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
CA2293718A1 (en) 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US20060257946A1 (en) * 2003-06-06 2006-11-16 Ciphergen Biosystems, Inc Serum biomarkers in ischaemic heart disease
EP1522857A1 (en) 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
ES2416344T3 (es) * 2004-02-03 2013-07-31 Diadexus, Inc. Métodos para determinar la actividad de Lp-PLA2.
US9934294B2 (en) 2014-09-26 2018-04-03 Wal-Mart Stores, Inc. System and method for using past or external information for future search results

Similar Documents

Publication Publication Date Title
JP2013536408A5 (https=)
Blum et al. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis
JP2015503588A5 (https=)
JP2017528427A5 (https=)
JP2016517883A5 (https=)
IL292829B2 (en) Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk
JP2019533715A5 (https=)
Grover et al. The pleotropic role of statins: Could it be the imminent host modulation agent in periodontics?
RU2018133690A (ru) Лечение пациентов с гомозиготной семейной гиперхолестеринемией, получающих липидоснижающую терапию
Rogers et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin
JP2012505905A5 (https=)
Stein Management of dyslipidemia in the high-risk patient
JP2002525321A5 (ja) カテーテルによる血管再生を予防または遅らせる医薬組成物の製造のためのコレステロール低下剤の使用
Deedwania et al. Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials
JP2010505866A5 (https=)
JP4839309B2 (ja) 血栓症治療剤
JPWO2012046772A1 (ja) リンパ浮腫予防治療剤
MX2013007310A (es) Gemcabeno y derivados para tratar la pancreatitis.
Mason Update on statins
NZ603397A (en) Association of xanthine oxidase inhibitors and statins and use thereof
B Alonzo Myths and facts concerning the use of statins in very old patients
Pedersen Intensive lipid-lowering therapy for patients with aortic stenosis
Pedersen Overview of clinical trials on calcific aortic stenosis
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
RU2019134491A (ru) Предупреждение/уменьшение связанных с ишемией повреждений